Protein identified as potential druggable target for pancreatic cancer
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, and one of the most deadliest with a less than 10 percent, five-year survival rate. PRMT1 is involved in a number of genetic processes including gene transcription, DNA repair and signaling.
“Our study has identified and validated for the first time...
MD Anderson celebrates the mission of Kick Butts Day
As an institution devoted to eliminating cancer, The University of Texas MD Anderson Cancer Center proudly supports the mission of Kick Butts...
Monoclonal antibody drug superior to chemotherapy for advanced acute lymphoblastic leukemia
A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard...
MD Anderson study ties protein ‘reader’ ENL to common leukemia
Anyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid leukemia (AML), a fast-growing cancer of bone marrow and blood cells and the second most common type of leukemia in children and adults.
Findings from a study at The University of Texas MD Anderson Cancer Center revealed the leukemia-boosting abilities of ENL, which contains a protein...
